EA200401448A1 - METHOD OF PROTECTION OF ENDOTHELIAL AND EPITHELIAL CELLS DURING CHEMOTHERAPY - Google Patents

METHOD OF PROTECTION OF ENDOTHELIAL AND EPITHELIAL CELLS DURING CHEMOTHERAPY

Info

Publication number
EA200401448A1
EA200401448A1 EA200401448A EA200401448A EA200401448A1 EA 200401448 A1 EA200401448 A1 EA 200401448A1 EA 200401448 A EA200401448 A EA 200401448A EA 200401448 A EA200401448 A EA 200401448A EA 200401448 A1 EA200401448 A1 EA 200401448A1
Authority
EA
Eurasian Patent Office
Prior art keywords
endothelial
protection
epithelial cells
cells during
during chemotherapy
Prior art date
Application number
EA200401448A
Other languages
Russian (ru)
Other versions
EA008213B1 (en
Inventor
Гюнтер Айсснер
Эрнст Холлер
Original Assignee
Клиникум Дер Униферситет Регенсбург
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Клиникум Дер Униферситет Регенсбург filed Critical Клиникум Дер Униферситет Регенсбург
Publication of EA200401448A1 publication Critical patent/EA200401448A1/en
Publication of EA008213B1 publication Critical patent/EA008213B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к применению защитного олигодезоксирибонуклеотида для лечения пациента, подвергающегося лечению иммунодепрессантом. Данное изобретение также относится к фармацевтической композиции, содержащей терапевтически эффективную дозу иммунодепрессанта и защитного олигодезоксирибонуклеотида.Международная заявка была опубликована вместе с отчетом о международном поиске.The present invention relates to the use of a protective oligodeoxyribonucleotide for treating a patient undergoing treatment with an immunosuppressant. This invention also relates to a pharmaceutical composition comprising a therapeutically effective dose of an immunosuppressant and a protective oligodeoxyribonucleotide. The international application was published along with an international search report.

EA200401448A 2002-05-31 2003-06-02 Method for the production of endothelial and epithelial cells during chemotherapy EA008213B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38411402P 2002-05-31 2002-05-31
US38743802P 2002-06-11 2002-06-11
PCT/EP2003/005753 WO2003101468A1 (en) 2002-05-31 2003-06-02 Method for the protection of endothelial and epithelial cells during chemotherapy

Publications (2)

Publication Number Publication Date
EA200401448A1 true EA200401448A1 (en) 2005-06-30
EA008213B1 EA008213B1 (en) 2007-04-27

Family

ID=29715309

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401448A EA008213B1 (en) 2002-05-31 2003-06-02 Method for the production of endothelial and epithelial cells during chemotherapy

Country Status (16)

Country Link
EP (1) EP1509235A1 (en)
JP (1) JP2005527636A (en)
CN (1) CN1304011C (en)
AU (1) AU2003238189A1 (en)
CA (1) CA2487171A1 (en)
EA (1) EA008213B1 (en)
HR (1) HRP20041213A2 (en)
IL (1) IL165353A0 (en)
IS (1) IS7548A (en)
MX (1) MXPA04011941A (en)
NO (1) NO20045655L (en)
NZ (1) NZ536864A (en)
PL (1) PL374402A1 (en)
RS (1) RS102504A (en)
UA (1) UA83628C2 (en)
WO (1) WO2003101468A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031714A1 (en) * 2003-09-05 2005-03-06 Gentium Spa FORMATIONS FOR ANTITUMORAL ACTION.
CN103260627A (en) * 2010-11-12 2013-08-21 真蒂奥姆有限公司 Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd).
DK2864496T4 (en) 2012-06-22 2021-01-04 Gentium S R L EUGLOBULIN-BASED PROCEDURE FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTID
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1202750A4 (en) * 1997-04-28 2002-10-16 Arsinur Burcoglu Method of treating hiv infection and related secondary infections thereof

Also Published As

Publication number Publication date
UA83628C2 (en) 2008-08-11
NZ536864A (en) 2008-08-29
HRP20041213A2 (en) 2006-04-30
EA008213B1 (en) 2007-04-27
NO20045655L (en) 2004-12-27
JP2005527636A (en) 2005-09-15
IS7548A (en) 2004-11-24
EP1509235A1 (en) 2005-03-02
AU2003238189A1 (en) 2003-12-19
IL165353A0 (en) 2006-01-15
MXPA04011941A (en) 2005-07-26
PL374402A1 (en) 2005-10-17
CN1304011C (en) 2007-03-14
CA2487171A1 (en) 2003-12-11
CN1655801A (en) 2005-08-17
WO2003101468A1 (en) 2003-12-11
RS102504A (en) 2006-12-15

Similar Documents

Publication Publication Date Title
MXPA05013642A (en) Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer.
EA199900137A1 (en) SUBSTITUTED PYRIDINES AS A ELECTORAL CYCLOOXIGASE-2 ELECTOR INHIBITORS
EA200401471A1 (en) APPLICATION OF CETR INHIBITORS AND POSSIBLE INHIBITORS OF HMG COA AND / OR ANTIHYPERTENSIVE AGENTS
BRPI0414533A (en) compound, pharmaceutical composition, and methods for inhibiting an hsp90 and treating an individual having an hsp90 mediated disorder
EA200100992A1 (en) IMPDH ENZYME INHIBITORS
EA200300788A1 (en) DERIVATIVES OF SUBSTITUTED ALKYLAMINS AND THEIR APPLICATION
BRPI0409128A (en) use of peripheral opioid antagonists, especially methylnaltrexone to treat irritable bowel syndrome
MXPA02012272A (en) Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv.
NO20034204L (en) Pharmaceutical combinations for the treatment of cancer
HK1091127A1 (en) Compounds and methods for downregulating the effects of tgf-beta
EA200000911A1 (en) NEW CRYSTAL FORMS OF ANTI-VIRUS COMPOUND OF BENZIMIDAZOLE
DK1664016T3 (en) Therapeutic agents useful for the treatment of pain
NO20024646L (en) Combination therapies with vasculature-damaging activity
ATE419857T1 (en) USE OF LAXATIVES TO TREAT IRRITABLE BOWEL SYNDROME
EA200600921A1 (en) METHODS AND COMPOSITIONS WITH THE USE OF TALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF CANCER AND OTHER DISEASES
IS7315A (en) Replaced diketopiperazine as an oxytocin antagonist
EA200500894A1 (en) APPLICATION OF A COMBINATION CONTAINING A NON-NUCLEOSIDE INHIBITOR REVERSE TRANSCRIPTASIS (NNIOT) IN COMBINATION WITH A CYTOCHROME P450 INHIBITOR SO AS PROTEASE INHIBITORS
EA200200502A1 (en) METHOD OF INTRODUCTION OF PHOSPHODYSTRASE 4 INHIBITOR
DE69625682D1 (en) METHOD FOR TREATING IGNITIONS AND COMPOSITIONS THEREFOR
EA200401448A1 (en) METHOD OF PROTECTION OF ENDOTHELIAL AND EPITHELIAL CELLS DURING CHEMOTHERAPY
DE60310742D1 (en) EXTRACT WITH ANTITUMORAL AND ANTITOXIC EFFECT
EA199800864A1 (en) METHOD OF TREATMENT FOR PATIENTS CAUSED BY MIGRAINE
EA199901061A1 (en) NEW SALTS OF HRV-PEPTIDES WITH ORGANOPROTECTIVE ACTIVITY, METHOD OF THEIR RECOVERY AND THEIR USE IN THERAPY
ATE428418T1 (en) AGENTS COOPERATE WITH A SEROTONIN TRANSPORTER FOR CANCER TREATMENT
DE60221104D1 (en) SUBSTITUTED DIARYL HARVES AS STIMULATORS OF FAS-MEDIATED APOPTOSIS

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU